Novo's Oral Wegovy Beats Rival Pill to EU Approval

Novo Nordisk secures the first EU-wide clearance for an oral GLP-1, ahead of Eli Lilly's competing pill.

17 Jul 2026

The European Commission has approved Novo Nordisk's once-daily Wegovy pill for weight management, making it the first oral GLP-1 receptor agonist cleared across all EU member states. The decision gives the Danish drugmaker a head start over its main rival in the race to dominate Europe's weight-loss pill market, since the competing small-molecule pill has not yet secured equivalent clearance.

The approval covers oral semaglutide at 25 milligrams for adults with a body mass index of at least 30, or at least 27 with a weight-related health condition, used alongside diet and exercise. Novo Nordisk said clinical trial data supporting the decision showed patients on the pill lost an average of roughly 17 percent of body weight, compared with about three percent among those on placebo, following a positive recommendation from European regulators in May.

A specialized absorption enhancer and strict fasting rules around dosing allow the oral formulation to achieve meaningful bioavailability in tablet form, since the underlying molecule is a peptide. That contrasts with the rival non-peptide pill under development, which its maker has positioned as easier to manufacture at scale and simpler to take without food or water restrictions. These mechanistic and manufacturing differences are increasingly shaping how each company frames its pricing and access strategy across European markets.

Already sold in the United States, the United Kingdom, and the United Arab Emirates, the pill is set to reach additional European countries during the second half of the year, Novo Nordisk said. Executives described the approval as more than a regulatory milestone, framing it as part of a broader societal response to obesity across the continent, even as national pricing and reimbursement talks will ultimately determine how quickly patients gain access.